ADAKVEO 10 mg/ml, concentrate for solution for infusion bottle, 10 ml
Active ingredients: Crizanlizumab
Commercialized according to BDPMDispensing in France: Prescription only, hospital use
Concentrate for solution for infusionbottle, 10 mlintraveineuse
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ADAKVEO 10 mg/mL, solution à diluer pour perfusion
- Pharmaceutical form
- solution à diluer pour perfusion
- Route of administration
- intraveineuse
- Presentation description
- 1 flacon(s) en verre de 10 ml
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 3 Aug 2023
- Prescription and dispensing conditions
- Prescription only, hospital use
- List I: prescription-only medicine
- Prescribed by specialists only
- Hospital use only
- Enhanced ANSM monitoring
- Yes
BDPM identifiers
CIS
62004984CIP75507553CIP133400955075530Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CRIZANLIZUMABsolution | 10 mg · 1 mL de solution à diluer | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.